MATTHEW
HUDSON.

Matthew Hudson | Health Technology Assessment (HTA) Expert

Director & HTA Expert

  • “I would highly recommend him - he has great HTA skills, strong project management ability and [a] great commercial perspective too.”

    Executive Director, Market Access and Reimbursement

  • “It has been an absolute pleasure working with you and I look forward to more hours of collaboration”

    Senior Product Manager, CAR T-cell therapy

  • “Matthew has done a fantastic job and his technical ability and diligence have sat at the centre of three really strong access strategies”

    Director, Market Access and Reimbursement

  • “This effort from your side is a clear example of the company’s core values, particularly Teamwork and Excellence.”

    Senior Director, Value & Access, Global Pricing and Analytics

  • “[Matthew] has been rock solid in his commitment to deliver, and for the technical skills he brought to this build.”

    Senior Director, Market Access and Reimbursement - UK & Ireland

Experience

  • Biosimilars, Cardiovascular, Central Nervous System, COVID-19, Endocrine, Gastrointestinal System, Haematology, Immunology, Infections, Joint replacement, Metabolism, Musculoskeletal Diseases, Obs Gynae & Urinary-tract, Oncology (including CAR-T), Ophthalmology, Orphan Disease, Respiratory, Ultra-orphan Diseases, Virology.

  • AbbVie, Alcon, Amgen, Astellas, Baxter, Bristol-Myers Squibb, Celltrion, GE Healthcare, Gilead, GlaxoSmithKline, Johnson & Johnson, Kite, Napp, Norgine, Novartis, Novo Nordisk, Pfizer, Sanofi, Shire.

  • MSc Operational Research, University of Lancaster

    MEd Teaching and Learning, University of Sheffield

    MSt Entrepreneurship, University of Cambridge

  • Abstract reviewer, 2021 Canadian Agency for Drugs and Technologies in Health (CADTH) Symposium (Nov 2021).

    Research abstract reviewer, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe 2020 Virtual Congress (Nov 2020).

    Research abstract reviewer, ISPOR 2020 International Congress (Orlando, May 2020).

    Research abstract review committee, ISPOR 2019 (New Orleans, May 2019).

    Reviewed research on methods studies for the 19th Annual European Congress of ISPOR (Vienna, Nov 2016).

    Reviewed costing studies for 18th European Congress of ISPOR (Milan, Nov 2015).

    Reviewed costing studies for 20th International Meeting of ISPOR (Philadelphia, May 2015).

    Judged podium presentations on ‘Research on Methods – Modelling Studies’ at 17th Annual European Congress of ISPOR (Amsterdam, Nov 2014).

    Judged podium presentations on ‘Studies on NICE Assessments’ at 17th Annual European Congress of ISPOR (Amsterdam, Nov 2014).

    Judged podium presentations on ‘Systemic disorders/Conditions’ at 17th Annual European Congress of ISPOR (Amsterdam, Nov 2014).

  • Health Technology Assessment International (HTAi)

    International Society for Pharmacoeconomics and Outcomes Research (ISPOR)

    Operational Research Society (ORS)

    Royal Pharmaceutical Society (RPS)

    Royal Society for Public Health (RSPH)

  • Pharmaceutical Scientist member of the Royal Pharmaceutical Society (SRPharmS)

    Fellow of the Royal Society for Public Health (FRSPH)

    Associate Fellow of the Operational Research Society (AFORS)

    Fellow of the Higher Education Academy (FHEA)

    Honorary Lecturer in Applied Health Economics, University of South Wales

    Homerton College Master’s Prize, University of Cambridge

    European Hematology Association (EHA) Abstract Award

    ISPOR Poster Presentation Award

    Market Access Award, Boehringer Ingelheim

    Inspire Award, Johnson & Johnson

    G-Thanks Award, Gilead Sciences

  • Ambassador for Judge Business School, University of Cambridge

    Chair of Scientific Committee, Emirates Health Economics Society

    (Former) Task Force Member at the Association of British Pharmaceutical Industries (ABPI)

    (Former) UK PharmaScan Horizon Scanning Champion for Boehringer Ingelheim

    (Former) Chair of the Oncology Market Access Materials Group at Boehringer Ingelheim